| Literature DB >> 34943049 |
Gerardo Tricarico1,2, Valter Travagli3.
Abstract
In the last twenty years there has been a proliferation of articles on the therapeutic use of ozone. As it is well-known, the term ozone therapy is very broad. It ranges from either systemic or loco-regional administration of unstable gaseous oxygen/ozone mixtures to the topical application of stable ozonated derivatives. Anyway, in relation to the absence of specific receptors and the extreme reactivity with the biological liquids with which it comes into contact, gaseous ozone cannot be classified as either a drug or a pro-drug. When the gaseous ozone impacts a biological matrix, both reactive oxygen species (ROS) and lipid oxidation products (LOPs) are formed. They represent the effector molecules responsible for modulating the therapeutic activity in the body. Apart from the merits of the action mechanisms resulting from the use of ozone, this article seeks to validate the practice of ozone therapy as an adjuvant treatment in full compliance with the physiology of the whole organism.Entities:
Keywords: blood; immunomodulation; lipid ozonation products; oxidative stress; oxidative therapies; ozone therapy; reactive oxidative species
Year: 2021 PMID: 34943049 PMCID: PMC8750071 DOI: 10.3390/antiox10121946
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Resonance structures of the ozone molecule.
Figure 2Schematic representation of the key molecular mechanisms of action of the ozone on the blood and intravascular compartment during M-AHT.
Clinical trials attributable to major autohemotherapy.
| Title | Identifier (Location) |
|---|---|
| Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure (CORMOR) | NCT04388514 (Italy) |
| Oxygen–Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora (PROBIOZOVID) | NCT04366089 (Italy) |
| Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID-19) in Non-intubated Patients (Ozono COVID-19) | NCT04359303 (Spain) |
| Ozone Autohemotherapy for COVID-19 Pneumonia (COVID-19 OZONE) | NCT04370223 (Spain) |
| Ozone Therapy in the Prevention of COVID-19 Infection | NCT04400006 (Turkey) |
| Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B (EMOTCHB) | NCT01342185 (China) |
| Oxygen-ozone Therapy Plus Antibiotic Therapy in the Treatment of Infections Secondary to Implant of Orthopaedic Devices | NCT04787575 (Italy) |
| Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000030165 (China) |
| A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19) | ChiCTR2000030006 (China) |
| Study for improvement of myocardial ischemia-reperfusion injury after perioperative cardiopulmonary bypass by ozone autotransfusion combined with electroacupuncture point therapy | ChiCTR2000029612 (China) |
| Synergy effects and health regulation effect of oxygen-ozone therapy on systemic lupus erythematosus (SLE) | ChiCTR-IOR-17012802 (China) |
| Ozone treatment for Acute Ischemic Stroke within 1 w of Symptom Onset: A Prospective, Randomized, Multi-center, Open-label, Parallel control, Comparative Study | ChiCTR-ICR-15007093 (China) |
| A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19) | ChiCTR2000030102 (China) |
| The effect of ozone treatment on serum markers in patients with fatty liver disease | ChiCTR-TNRC-11001273 (China) |
| Effect of Ozone therapy in the treatment of COVID-19 | IRCT20191125045492N2 (Iran) |
| A study of therapeutic effect of blood ozone therapy of severe COVID-19 patients | IRCT20200616047792N1 (Iran) |
| Investigation of the effects of medical Ozone Autohemotherapy on clinical and paraclinical features of patients with COVID-19 | IRCT20190618043923N4 (Iran) |
| Comparison of the effectiveness of Ozone therapy with conventional therapy in the improvement of visual pathways function in diabetic patients | IRCT20191125045492N1 (Iran) |
| Ozone therapy and routine medical treatment efficacy on serum level changes of TNF-α and CRP as well as neurological improvement | IRCT20200202046342N1 (Iran) |
| Ozone Therapy Effect on Multiple sclerosis | IRCT20171105037262N3 (Iran) |
Average molecules/mL of readily available antioxidants and PUFA in human plasma with respect to ozone molecules/mL in the oxygen/ozone gaseous mixture at the different concentrations used at therapeutic level.
| Non-Enzymatic Antioxidants and Polyunsaturated Fatty Acids (PUFA) Levels, | |||||||
|---|---|---|---|---|---|---|---|
| Uric acid ~1.1019 molecules/mL | |||||||
| Ascorbic acid ~1.7 × 1018 molecules/mL | |||||||
| Glutathione ~1.1 × 1017 molecules/mL | |||||||
| Albumin ~2.6 × 1019 molecules/mL | |||||||
| Available PUFA ~2.4 × 1019 molecules/mL | |||||||
| [O3, μg/mL] | 10 | 15 | 20 | 25 | 30 | 35 | 40 |
| No. O3 molecules/mL (×1019) | 1.3 | 2.0 | 2.6 | 3.3 | 3.9 | 4.6 | 5.2 |